We have measured unconjugated urinary dopamine and investigated its relationship to glomerular filtration rate in two groups of 22 patients with chronic renal failure matched for age and sex, one group with primary glomerular disease, the other with tubulo-interstitial disease. Urine dopamine excretion was similar in both glomerular and tubulo-interstitial disease groups, and correlated significantly with creatinine clearance. Although urinary protein excretion was significantly higher in glomerular disease, urinary sodium excretion, fractional sodium excretion, urine flow rate and free water clearance were similar in both groups and did not correlate with dopamine excretion. These results suggest that in patients with chronic renal disease, urinary dopamine excretion is mainly under the influence of the glomerular filtration rate, irrespective of the underlying pathology, and therefore interpretation of urinary dopamine excretion requires a knowledge of the patients' renal function.
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Animal and human studies have indicated that dopamine may have an important role in the regulation of renal function. Dopamine is produced in the kidney by the proximal tubular cells':" by the action of dopa-decarboxylase on dihydroxyphenylalanine (dopa). The rate limiting step in this process appears to be the availability of dopa to the tubular cells.! Both dietary salt and intravenous saline increase urinary dopamine excretion in mans and its temporal relationship to the natriuresis suggested that dopamine may be involved in controlling sodium excretion. Additional supporting evidence for dopamine as a natriuretic hormone was shown by administering carbidopa (a dopa decarboxylase inhibitor) to healthy volunteers.s Carbidopa reduced urinary dopamine excretion along with sodium excretion and these parameters correlated both before and during carbidopa therapy. Dopamine also has haemodynamic effects and may increase effective renal plasma flow and glomerular filtration rate. These changes alone may explain its natriuretic effects. However, the haemodynamic and natriuretic effects of dopamine have been dissociated during studies Correspondence: Dr P McClelland, 6C Link Unit, Royal Liverpool Hospital, Prescot Street, Liverpool L7 8XP, UK 646 using metoclopramide as a dopamine antagonist, supporting the role of dopamine as a natriuretic agent. 7 Sodium retention and hypertension are common features of chronic renal disease and could be related to abnormalities of dopamine metabolism. Casson et al. 8 noted that renal dopamine production in patients with chronic renal failure was reduced in response to dietary salt loading. The response to intravenous dopamine was also diminished in patients with renal failure? suggesting that dopamine may be important in the pathophysiology of chronic renal failure. Since dopamine is produced by the renal tubular cells it is possible that there may be differences in dopamine production and natriuresis in patients with primary glomerular disorders compared with patients with tubulointerstitial diseases.
Apart from its physiological role, urinary dopamine is a valuable adjunct in the investigation of catecholamine secreting tumours.? Patients with renal failure are frequently investigated for these tumours particularly to exclude other secondary causes of hypertension, so it would be important to establish the expected urinary excretion of dopamine for patients with chronic renal disease. We have, therefore, performed a prospective study, to investigate 24 h urinary dopamine excretion in patients with chronic renal disease of different aetiology.
PATIENTS AND METHODS
Forty-four patients were studied initially: 22 with biopsy proven predominantly glomerular disease (OD) and 22 with clinical, radiological or histological evidence of tubulo-interstitial disease (TID). Patient details are summarized in Table 1 . All the patients had been attending the Royal Liverpool Hospital as out-patients for at least 6 months. The two groups of patients studied were matched for creatinine clearance with comparable age ranges and sex ratios in each group. Thirteen patients with GD received diuretic therapy and seven of these were also receiving anti-hypertensive therapy compared with one receiving diuretics and five anti-hypertensive therapy in patients with TID (Table 1) . We subsequently extended the study to include a further 43 patients with renal failure, 26 with chronic renal failure of indeterminate cause, 10 with glomerulonephritis, three with lupus nephritis, two with diabetes, one with pyelonephritis and one with polyarteritis.
All patients attending the nephrology outpatients collect 24 h urine samples. Reliability of sampling was assessed by comparing the urinary creatinine content of each patient's two previous 24 h collections with the test sample. Twenty-four hour urine specimens were collected into bottles containing boric acid (10g) added as a preservative, the volume measured and an aliquot (10 mL) stored at -40°C. In-house studies had previously shown that dopamine was stable collected under these conditions for at least 2 months. Urinary dopamine (unconjugated/free) was measured by electrochemical detection after separation by ionpaired reversed-phase high performance liquid chromatography.10 A 1 mL aliquot of urine was extracted with alumina using well established procedures.lb'! Dihydroxybenzylamine was used Urine dopamine in chronic renal disease 647
as an internal standard to correct for extraction losses and as a chromatographic marker in the separation procedure. The electrochemical detection was carried out using a Coulochem detector (Severn Analytical, Shefford, UK) with the guard cell set at + O·35 V, detector cell 1 + O·05 V; the analytical cell -0 . 35 V and the gain settings on the analytical cell of 20 x 100 were appropriate for urine dopamine quantitation and calibration between 50-5000 nmol/L. The HPLC system included a Kratos Spectroflow 700 pump (Applied Biosystems Inc, Warrington, UK), a manual injector (Rheodyne valve 7120, Severn Analytical) and a CI8 reverse phase column (Spherisorb 5-0DS), or Ultratechsphere 5-0DS, 25 x O·46 em, (HPLC Technology, Macclesfield, UK). The mobile phase was as previously reported.'? The analytical precision of urine dopamine measurement was assessed using commercial controls L 1 and LII (available in freeze dried aliquots, Bio-Rad, Watford, UK). The coefficients of variation for within-batch assay were 9'70/0 and 10'2% (n = 8) and between batch 10' 4% and 8' 3% (n = 6) at measured dopamine concentrations of 980 and 1900nmol/L for Ll and LII, respectively. The recovery ± ISD of added dopamine to urine was 101± 7% (n = 8). The limit of detection using the analytical condition outlined was set at less than 50 nmol/L although the absolute limit by electrochemical detection is < 0 . 2 nmol/L.
Plasma creatinine, urinary creatinine, urea and electrolyte estimations were carried out using Technicon SMAC and flame emission procedures. Fractional sodium excretion was calculated by dividing the 24 h urinary sodium excretion by the creatinine clearance. Free water clearance was derived from calculated plasma and urine osmolarities using the relationship: urine volume x (I-urine osmolarity/plasma osmolarity).
Reliability of 24 h urine samples was tested using the paired r-test. Data from each group were compared using the Mann-Whitney U test. Correlation coefficients were calculated using Spearman's rank method and where multiple significant bivariate correlations were detected multiple regression analysis was applied to determine the dependent variables. A linear regression model was applied to urinary dopamine and creatinine clearance for all 87 patients. 
Number of patients

RESULTS
No significant differences were found in creatinine content between the test 24 h urine and the previous two samples (Sample 1: mean difference In the group of patients with GD, dopamine excretion correlated positively, using bivariate analysis, with creatinine clearance (r = O' 39, P<0'002, Fig. 1 ), urea excretion (r=0'45, P< 0'(01), potassium excretion (r=0'22, P<0'05) and negatively with age (r= -0'21, P<0·05) . Applying a multivariate analysis, significant regression coefficients (± standard error) were found with creatinine clearance (6' 8 ± 3 . I, P< O'025) and.urea excretion (3'5± 1'1, P<0·OO5) only.
In patients with TID, urinary dopamine excretion correlated positively with creatinine A summary of the data obtained (Table 2 ) shows that the mean 24 h urinary excretion of dopamine, sodium, potassium and urea in GD was not significantly different from TID. The mean creatinine clearance, fractional sodium excretion, urine flow rate, and free water clearance were also similar in both groups. The only factor which differentiated the two groups was the increased proteinuria in GD. of the other measurements. No significant differences were found in urine dopamine and creatinine clearance between patients receiving diuretic therapy and those not receiving diuretics.
Using data from all the 87 patients investigated, the linear regression equation between urine dopamine (y) and creatinine clearance (x) was; r> 10'9±2'3 (x) + 311·9± 185·7 (,z=0'50, P<O'OOI; Fig. 2 ). Other measures of renal function were compared with urine dopamine to determine whether a random urine sample alone or even a random urine and random plasma sample would provide reliable information relating urine dopamine to renal function. Random urine creatinine values correlated poorly with urine dopamine (Fig. 3a) and also with plasma creatinine (Fig. 3b ), better use of this parameter is demonstrated by using the reciprocal of plasma creatinine (Fig. 3c ), which is known to have a linear relationship with the glomerular filtration rate in progressive renal disease. 13 Urine creatinine (mmoI/24h) clearance (,z=0'67, P<O'OOI, Fig. 1 ) and potassiurn excretion (,z = O' 25, P < 0 . 05) only.
Using multiple regression analysis, the regression coefficient was significant only between creatinine clearance and dopamine excretion (14'1 ±4'9, P<0·OO5).
The 24 h urinary sodium excretion was similar in both groups and was not correlated with either dopamine excretion or creatinine clearance. Proteinuria was significantly greater in GD (2'9±0'8 g/24 h) than in TID (0'3 ±0·1 g/24 h, P<O'OOI) but did not correlate with any decreased with decreasing glomerular filtration rate. The reduction in dopamine excretion is most likely due to a fall in available plasma L-dopa as this is the main source of urinary dopamine," circulating dopamine being present in such small amounts as to make little contribution. The relationship of urine dopamine to glomerular filtration rate would suggest that dopa delivery and filtration is the major factor in determining dopamine appearance in the urine. Other contributory factors could include loss of dopa decarboxylase activity through selective damage to proximal tubular cells or, as a result of uraemic toxins, an impairment in the synthesis of dopa precursors'v" or possibly a failure of dopamine deconjugation. The consistent significant relationship between creatinine clearance and urine dopamine in patients with either glomerular pathology or tubulo-interstitial disease suggests it is progressive nephron loss and reduced glomerular filtration that is the most important factor in determining urinary dopamine. Our findings have been reinforced by extending the analysis to other patients with chronic renal disease and we have developed a linear regression model to provide a reference range for patients with renal failure (Fig. 2) . The use of creatinine corrected values for urine dopamine has previously been used to improve the value of this measurement for diagnostic purposes. 9 However, we found a weaker correlation between plasma or urine creatinine and urine dopamine. This is not surprising because the relationship between plasma creatinine and glomerular filtration is not linear. 13 We could find little evidence to link urinary dopamine and 24 h sodium excretion in patients with chronic renal failure. In part, the dopaminergic responses to salt loading may be explained by increases in GFR, and changes in other intrarenal hormones such as renin may be contributory." Recent evidence suggests that the sympathetic nervous system also has a role to play in the response to a salt load." Autonomic dysfunction occurs in chronic renal failure, which may suggest a further mechanism for the blunted response to a salt load in this condition. However, the contribution of renal nerves to dopamine excretion is only a small proportion of the total unless the patient has a catecholamine secreting lesion, and so is unlikely to be responsible for our findings. The normal regulation of sodium excretion is under many influences and from our study we cannot exclude a role for dopamine in the fine tuning of this response.
The infusion of dopamine produces little effect on natriuresis until doses of 2 JLg/kg/min are used, producing plasma dopamine levels more than ten times above the normal circulating plasma level, showing it to be effective at a pharmacological, rather than a physiological level. A blunted pharmacological effect might be expected in chronic renal disease if progressive nephron loss were associated with loss of, or down-regulation of, available dopamine receptors in contrast to the effect of dopamine in acute renal failure where the nephron mass is maintained and significant increases in natriuresis are seen. I? Urinary dopamine can be increased by dietary protein" and this may in part be responsible for the increases in GFR and natriuresis that have been reported following a meat meal'? or amino acid infusion.P Such a relationship would help to explain the correlation of urinary dopamine with urinary urea and potassium. However, we cannot explain the differential effects in GD and TID. Normally urea is reabsorbed by the renal tubules and loop of Henle, particularly in low urine flow states. However, we could fmd no differences in free water clearance or urine flow rates to account for the disparity between the two groups. It would obviously be interesting to compare the effects of dietary protein restriction and supplementation on urinary dopamine excretion in different renal diseases.
In conclusion, we suggest that in patients with chronic renal disease urinary dopamine excretion is closely related to the prevailing renal function. This should be borne in mind when interpreting such measurements and, if possible, corrected to creatinine clearance where reliable 24 h collections can be made, or related to the reciprocal of plasma creatinine concentration as the next best correlate to glomerular filtration rate.
